Viewing Study NCT00782093


Ignite Creation Date: 2025-12-25 @ 1:26 AM
Ignite Modification Date: 2026-05-22 @ 5:48 AM
Study NCT ID: NCT00782093
Status: COMPLETED
Last Update Posted: 2024-02-21
First Post: 2008-10-29
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration
Sponsor:
Organization: